Printed from Voxsanity (voxsanity.com.au) — NCT07619599 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 1 Lung Cancer Trial, Recruiting
NCT07619599
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person joining the trial (and/or their legal representative) must have given documented informed consent, and agreement from the participant themselves will also be sought where appropriate.
- Adults aged 18 years or older.
- People whose ability to carry out daily activities is not severely limited by their illness (as measured by a standard medical scale called ECOG, with a score of 2 or lower).
- People who have been confirmed through a tissue sample (biopsy) to have stage IV non-small cell lung cancer.
- People who are currently being treated with the immunotherapy drug pembrolizumab on its own, and who have been referred for a type of focused radiation treatment called SBRT because their cancer has continued to grow in a limited number of areas (up to 6 sites on this trial).
- The areas planned for SBRT radiation must be located in lymph nodes, bones/spine, or the lungs.
- People who have cancer that has spread to the brain are able to participate, but at least one area outside the brain must also be planned to receive SBRT.
- People whose blood test results show an adequate level of a type of white blood cell called neutrophils (at least 1,000 per mm³).
- People whose platelet count (cells that help blood clot) is at least 50,000 per mm³, without having received a platelet transfusion in the 14 days before that measurement.
- People whose liver function blood tests (bilirubin, AST, and ALT) are within acceptable ranges as defined by the trial.
- People whose kidneys are filtering at an adequate rate (creatinine clearance of at least 30 mL/min, measured by a urine or formula-based test).
- Women who could become pregnant must have a negative pregnancy test (urine or blood) before joining.
- People who are capable of having children (men and women who have not been surgically sterilised, or women who have not gone without a menstrual period for more than one year) must agree to use effective contraception or avoid heterosexual activity during the study and for at least 6 months after the last treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose doctor plans to stop pembrolizumab at the time they are being referred for SBRT.
- People who have received a live attenuated vaccine (a type of vaccine made with a weakened live virus) within 4 weeks before starting the study treatment, except for upcoming COVID-19 or flu vaccines.
- People who are currently using, or have used within the past 14 days, medications that suppress the immune system — with certain exceptions, including: nasal sprays, creams, or inhaled steroids; local steroid injections (such as into a joint); low-dose daily steroids (up to 5 mg of prednisone or equivalent); or steroids used to prevent allergic reactions to treatments or scans.
- People who have had allergic reactions to medications that are chemically or biologically similar to the study drug.
- People with a significant uncontrolled medical illness.
- People who have had an infection requiring antibiotic treatment taken by mouth or by injection within 14 days before starting the study.
- People who are unable to tolerate a PET scan (a type of imaging scan) even with the help of calming medications.
- People who have another active cancer that could affect the safety or results of this trial (confirm with trial site).
- Women who are pregnant or breastfeeding.
- People with any other condition that, in the treating doctor's judgement, would make participation unsafe.
- People who, in the treating doctor's opinion, may not be able to follow all of the study requirements for practical or logistical reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
14 September 2026
Est. completion
22 December 2028
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Incidence of treatment-related adverse event rates; 64Cu-DOTA-pembrolizumab maximum standard uptake value (SUVmax)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.